Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies sodium fluorine-18 (18F NaF)/fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Positron Emission Tomography
  • Procedure: Magnetic Resonance Imaging
  • Radiation: Fludeoxyglucose F-18
  • Radiation: Fluorine F 18 Sodium Fluoride

Phase:

Phase 4

Eligibility


Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

   - Patient is ≥ 18 years old at the time of the drug administration

   - Patient provides written informed consent

   - Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
   PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

   - Patient is < 18 years old at the time of the drug administration

   - Patient is pregnant or nursing

   - Metallic implants (contraindicated for MRI)

   - Renal function impairment preventing administration of MRI contrast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All